title: [Diagnostic work-up and treatment of bladder cancer: current developments].
abstract: Forty percent of patients with superficial bladder carcinoma progress towards muscle-invasive carcinoma despite initial therapy. Emergent technologies in the diagnostics and therapy of superficial bladder carcinoma including fluorescence cystoscopy are able to reduce recurrence and progression rates. Nevertheless to date no trial was able to show a benefit with regard to cancer-specific and overall survival using these new technologies. Lymph vessel invasion has been introduced as a new prognostic marker in muscle-invasive bladder carcinoma that can be easily incorporated into routine clinical practice. Furthermore adjuvant chemotherapy has been identified along with lymph node density as a statistically significant marker for survival in muscle-invasive bladder carcinoma which should be investigated in prospective clinical trials. In metastatic bladder carcinoma, vinflunine was approved as second-line chemotherapy for patients who failed cisplatin-based chemotherapy. This article critically reviews the emergent developments of the last 12-15 months and comments on their clinical efficacy for the treatment of bladder carcinoma.
authors.affiliation: Klinik für Urologie und Kinderurologie, Universitätsklinikum des Saarlandes, Kirrbergerstrasse 1, 66421 Homburg/Saar. Carsten.Ohlmann@uks.eu
authors.forename: C-H
authors.initials: CH
authors.lastname: Ohlmann
authors.forename: M
authors.initials: M
authors.lastname: Stöckle
mesh_terms: D017024:Chemotherapy, Adjuvant / Q000639:trends; D003950:Diagnostic Techniques, Urological / Q000639:trends*; D006801:Humans; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis* / Q000628:therapy*; D014572:Urology / Q000639:trends*
references.citation: Urology. 2010 Sep;76(3):658-63
references.pmid: 20223505
references.citation: J Korean Med Sci. 2009 Aug;24(4):674-8
references.pmid: 19654951
references.citation: J Urol. 2009 Nov;182(5):2182-7
references.pmid: 19758623
references.citation: Int Braz J Urol. 2009 Nov-Dec;35(6):664-70; discussion 671-2
references.pmid: 20028572
references.citation: Eur Urol. 2010 Jun;57(6):1064-71
references.pmid: 20071073
references.citation: Eur Urol. 2010 Feb;57(2):300-9
references.pmid: 19766384
references.citation: Eur Urol. 2010 Feb;57(2):196-201
references.pmid: 19853987
references.citation: BJU Int. 2009 Aug;104(3):331-5
references.pmid: 19220265
references.citation: BJU Int. 2010 May;105(10):1402-12
references.pmid: 20132195
references.citation: Int J Urol. 2009 Mar;16(3):274-8; discussion 278
references.pmid: 19087211
references.citation: Eur Urol. 2009 Apr;55(4):773-80
references.pmid: 19153001
references.citation: Eur Urol. 2010 Feb;57(2):293-9
references.pmid: 19913351
references.citation: J Clin Oncol. 2009 Sep 20;27(27):4454-61
references.pmid: 19687335